Kathryn Golden

Kathryn Golden has extensive work experience in the biotechnology industry. Kathryn currently holds the position of Senior Vice President, Technical Operations & Cell Manufacturing at bit.bio since May 2022. Prior to this, Kathryn was a Co-Founder and Board Observer at Sunflower Therapeutics, where they played a key role in developing a drug production platform to reduce the time and cost of manufacturing biologics. Kathryn co-founded the company in September 2018 and served on the board until March 2023.

Kathryn also had a significant role at Q32 Bio Inc., where they started as a Senior Director CMC in April 2019 and eventually became the Vice President CMC. At Q32 Bio, they focused on developing therapies for severe autoimmune and inflammatory diseases by targeting the IL-7 pathway and complement system.

Before joining Q32 Bio, Kathryn worked as the Director of Manufacturing at Codiak Biosciences from March 2016 to April 2019. Kathryn was responsible for overseeing manufacturing operations. Prior to that, they held the position of Senior Scientist, Cell Culture Development and Manufacturing at Momenta Pharmaceuticals from July 2015 to March 2016. During this time, they led a perfusion-based biosimilar process development program.

Earlier in their career, Kathryn worked at Eleven Biotherapeutics as a Senior Scientist in various roles from November 2010 to July 2015. Kathryn was involved in upstream process development activities and successfully developed a fed-batch fermentation process for the production of a lead candidate for the treatment of dry eye disease. Kathryn also supervised the scale-up of the process to a 5000 L scale.

Kathryn's work experience also includes a role as a Scientist in Upstream Process Development at Percivia from February 2007 to November 2010. Kathryn led the development of a high-density perfusion process using PER. C6 cells.

Before entering the industry, Kathryn gained valuable experience at the Massachusetts Institute of Technology (MIT) as a Teaching Assistant and Lab Coordinator. During their time at MIT from January 2004 to February 2007, they conducted research on optimizing cell growth and monoclonal antibody productivity in perfusion systems.

Overall, Kathryn Golden has held positions of increasing responsibility and has made significant contributions to the biotechnology industry throughout their career.

Kathryn Golden pursued their education in a progressive and determined manner. Kathryn began their educational journey at Thomas Jefferson High School for Science and Technology, where they completed their high school education from 1997 to 2001.

Afterwards, they enrolled at the Massachusetts Institute of Technology and pursued a Bachelor of Science (S.B.) degree in Chemical Engineering. Kathryn dedicated herself to their studies from 2001 to 2005, acquiring a solid foundation in the field.

Seeking further specialization, Kathryn pursued a Master of Engineering (M.Eng.) in Bioengineering at the Massachusetts Institute of Technology from 2005 to 2007. This allowed their to deepen their knowledge in the interdisciplinary field of bioengineering.

Realizing the importance of business acumen, Kathryn then decided to pursue an advanced degree in management. Kathryn attended the MIT Sloan School of Management, where they completed their Master of Business Administration (MBA) degree from 2017 to 2019. This provided their with a well-rounded skill set and expertise in business administration.

To complement their education, Kathryn obtained additional certifications. In 2013, they became a certified Project Management Professional (PMP) through the Project Management Institute. Furthermore, they acquired a Lean Six Sigma Yellow Belt certification from the Project Management Academy in November 2015.

Overall, Kathryn Golden's educational path reflects their commitment to both technical and managerial skills, positioning their as a versatile professional with a strong foundation in engineering, bioengineering, and business administration.